38 related articles for article (PubMed ID: 22402083)
1. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
2. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H; Sakamoto H; Akita T; Ohyanagi F; Kawashima Y; Tambo Y; Tanimoto A; Horiike A; Miyauchi E; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2022 May; 13(10):1471-1478. PubMed ID: 35415873
[TBL] [Abstract][Full Text] [Related]
3. Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
Valet O; Swalduz A; Boussageon M; Buisson A; Avrillon V; Mastroïanni B; Pérol M
JTO Clin Res Rep; 2021 Jun; 2(6):100192. PubMed ID: 34590033
[TBL] [Abstract][Full Text] [Related]
4. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
[TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.
Esposito Abate R; Pasquale R; Sacco A; Piccirillo MC; Morabito A; Bidoli P; Finocchiaro G; Chiari R; Foltran L; Buosi R; Tiseo M; Giannetta L; Battiloro C; Fasola G; Romano G; Ciuffreda L; Frassoldati A; de Marinis F; Cappuzzo F; Normanno N
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31557965
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).
Song Y; Wu YL; Cao LJ; Chen JH; Ma ZY; Cui JW; Wang J; Liu HB; Ding JY; Hu M
Am J Clin Oncol; 2019 May; 42(5):432-439. PubMed ID: 30950859
[TBL] [Abstract][Full Text] [Related]
7. Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Onco Targets Ther; 2017; 10():4989-4995. PubMed ID: 29075129
[TBL] [Abstract][Full Text] [Related]
8. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.
Liu Z; Yao L; Tan B; Li L; Chen B
Oncol Lett; 2016 Dec; 12(6):5349-5355. PubMed ID: 28101246
[TBL] [Abstract][Full Text] [Related]
9. Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.
Zimmermann S; Peters S
EJC Suppl; 2013 Sep; 11(2):307-9. PubMed ID: 26217155
[No Abstract] [Full Text] [Related]
10. Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?
Zhao ZR; Li W; Long H
Sci Rep; 2014 Aug; 4():5996. PubMed ID: 25104233
[TBL] [Abstract][Full Text] [Related]
11. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Zhao ZR; Wang JF; Lin YB; Wang F; Fu S; Zhang SL; Su XD; Jiang L; Zhang YG; Shao JY; Long H
Med Oncol; 2014 Jan; 31(1):810. PubMed ID: 24338271
[TBL] [Abstract][Full Text] [Related]
12. The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Otsuka T; Kitai K; Kawase I
Chin J Cancer; 2013 Mar; 32(3):136-40. PubMed ID: 23237215
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Asahina H; Oizumi S; Inoue A; Kinoshita I; Ishida T; Fujita Y; Sukoh N; Harada M; Maemondo M; Saijo Y; Dosaka-Akita H; Isobe H; Nukiwa T; Nishimura M;
Oncology; 2010; 79(5-6):423-9. PubMed ID: 21474967
[TBL] [Abstract][Full Text] [Related]
15. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
16. The role of gefitinib in lung cancer treatment.
Giaccone G
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
[TBL] [Abstract][Full Text] [Related]
17. Brain metastasis responding to gefitinib alone.
Poon AN; Ho SS; Yeo W; Mok TS
Oncology; 2004; 67(2):174-8. PubMed ID: 15539923
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
